EcoVadis rating validates Boyds’ business sustainability commitments and performance.
Global drug development consultancy, Boyds is pleased to announce that it has achieved a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.
In the company’s latest rating, which was completed in April 2026, Boyds scored 65 out of 100, which places Boyds in the top 35% of companies globally.
Commenting on the achievement, Boyds’ CEO, Professor Alan Boyd MBE said: “Achieving an EcoVadis Bronze Medal is an important milestone for Boyds and reflects the commitment we have made…
MDC welcomes new Chair from January 2027 to drive impact as next-generation technologies and collaborations reshape drug discovery
Medicines Discovery Catapult (MDC) is delighted to announce today the selection of its next Chair of the Board. Professor Sir Mike Ferguson will take up the position from the beginning of 2027, succeeding Dr Robin Brown, who expertly led the organisation as Chair for nine years.
A transition period will follow, with Robin vacating the post at the end of December this year, having completed his valuable service to the Catapult. MDC is deeply grateful for the…
BioInnovation Institute (BII), a leading institute for life science and deep tech start-ups, has chosen Victoria House in London as the location for its UK base – the first research space outside of its headquarters in Copenhagen - marking a major milestone in BII’s expansion of translational innovation across Europe.
The London hub, which was developed by Pioneer Group and Oxford Properties, will serve as the flagship site for BII’s newly launched CardioMetabolic Bridge initiative - a pan-European effort backed by the Novo Nordisk Foundation and designed to accelerate the translation of…
Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), and BGF join existing investors Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures
Cambridge, UK, 23 June 2026: TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in…
LONDON, UK, ZUG, Switzerland and STOCKHOLM, Sweden – June 23, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Cellcolabs and is pleased to announce the placement of Vincent Metzler, Ph.D., as Chief Executive Officer (CEO). Cellcolabs is a Swedish biotechnology company specializing in the large-scale, industrial production of high-quality mesenchymal stromal cells (MSCs) to prevent and treat debilitating and life-threatening diseases.Dr. Metzler joins the company at a critical…
The Awards are taking place on 10 December 2026 at 1 Wimpole Street, London, UK at the Genesis conference!
The One Nucleus Awards has been integrated into the Genesis Conference, to recognise outstanding achievements across our ecosystem. All shortlisted companies will receive a free delegate pass and will be invited to pitch at the company showcase, plus having the opportunity to network with over 400 delegates.
Combining the annual Genesis Conference and Annual Awards celebration provides Life Science innovators, companies and their support ecosystem with the opportunity to connect,…
More than 1,600 local students from 49 schools across east Kent have taken part in the region’s largest ever science jamboree.
The annual two-day event, held at Discovery Park in Sandwich, transformed the science and business park into a hub of exploration and hands-on learning, bringing together young people, businesses and universities to learn about the world of science, technology, engineering and mathematics (STEM).
Organised by STEM Hub at Canterbury Christ Church University, the jamboree delivers a range of exciting practical scientific experiments and activities for the students to…
LONDON, UK – June 16, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Cancer Research Horizons and is pleased to announce the placements of Heather Preston, Richard Wooster and Hans Bishop as Non-Executive Directors (NEDs) to its Board. Cancer Research Horizons is the innovation arm of Cancer Research UK. Its strategy focuses on working directly with researchers to help them maximize the impact of their work, providing funding, expertise and advice to translate…
Oxford, UK - 17 June 2026 - PrecisionLife has launched Biology Matters, a new podcast exploring how advances in biology, genomics, data science, and AI can help address one of healthcare's greatest challenges: chronic disease.The podcast's debut episode features hosts and PrecisionLife co-founders Steve and Rowan Gardner discussing the growing impact of chronic disease on patients, healthcare systems, and society, and the opportunities emerging from advances in precision medicine.Future episodes will feature leaders from across healthcare, biopharma, technology, research, and…
Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.
Every antibody in the new catalogue has been subject to rigorous validation technologies to confirm that they selectively recognize their intended targets across applications such as immunohistochemistry, western blot, flow cytometry and immunofluorescence. These recombinant and monoclonal antibodies also provide high sensitivity and minimal background…